- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 193048, 5 pages
Role of Dopaminergic Receptors in Glaucomatous Disease Modulation
1Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00161 Rome, Italy
2Department of Sense Organs, Centre of Ocular Electrophysiology, Sapienza University of Rome, Piazzale Aldo Moro 5, 00161 Rome, Italy
Received 14 April 2013; Revised 6 June 2013; Accepted 12 June 2013
Academic Editor: Paolo Fogagnolo
Copyright © 2013 Nicola Pescosolido et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. A. Quigley and A. T. Broman, “The number of people with glaucoma worldwide in 2010 and 2020,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 262–267, 2006.
- H. A. Quigley, “Glaucoma,” The Lancet, vol. 377, no. 9774, pp. 1367–1377, 2011.
- Y. Zhong, J. Wang, and X. Luo, “Integrins in trabecular meshwork and optic nerve head: possible association with the pathogenesis of glaucoma,” Journal of Biomedicine and Biotechnology, vol. 2013, Article ID 202905, 8 pages, 2013.
- N. Pescosolido, C. Cavallotti, D. Rusciano, and M. Nebbioso, “Trabecular meshwork in normal and pathological eyes,” Ultrastructural Pathology, vol. 36, no. 2, pp. 102–107, 2012.
- G. Scarsella, M. Nebbioso, S. Stefanini, A. Librando, and N. Pescosolido, “Degenerative effects in rat eyes after experimental ocular hypertension,” European Journal of Histochemistry, vol. 56, no. 4, article e42, pp. 265–271, 2012.
- R. F. Brubaker, “Measurement of uveoscleral outflow in humans,” Journal of Glaucoma, vol. 10, no. 5, pp. S45–S48, 2001.
- C. Cavallotti, N. Pescosolido, V. Pescosolido, and G. Iannetti, “Determination of dopamine D1 receptors in the human uveo scleral tissue by light microscope autoradiography,” International Ophthalmology, vol. 23, no. 3, pp. 171–179, 2001.
- S. Kingman, “Glaucoma is second leading cause of blindness globally,” Bulletin of the World Health Organization, vol. 82, no. 11, pp. 887–888, 2004.
- K. Green, A. Hensley, and G. Lollis, “Dopamine stimulation of passive permeability and secretion in the isolated rabbit ciliary epithelium,” Experimental Eye Research, vol. 29, no. 4, pp. 423–427, 1979.
- B. Libet, “Which postsynaptic action of dopamine is mediated by cyclic AMP?” Life Sciences, vol. 24, no. 12, pp. 1043–1057, 1979.
- M. D. Lograno, E. Daniele, and S. Govoni, “Biochemical and functional evidence for the presence of dopamine D1 receptors in the bovine ciliary body,” Experimental Eye Research, vol. 51, no. 5, pp. 495–501, 1990.
- D. E. Potter, “Do dopamine and dopamine receptors have roles in modulating function in the anterior segment? The evidence,” Progress in Retinal and Eye Research, vol. 15, no. 1, pp. 103–111, 1996.
- C. Prünte, I. Nuttli, R. Markstein, and C. Kohler, “Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits,” Journal of Neural Transmission, vol. 104, no. 2-3, pp. 111–123, 1997.
- C. Bucolo, G. M. Leggio, A. Maltese, A. Castorina, V. D'Agata, and F. Drago, “Dopamine-3 receptor modulates intraocular pressure: implications for glaucoma,” Biochemical Pharmacology, vol. 83, no. 5, pp. 680–686, 2012.
- R. P. Shannon, A. Mead, and M. L. Sears, “The effect of dopamine on the intraocular pressure and pupil of the rabbit eye,” Investigative Ophthalmology, vol. 15, no. 5, pp. 371–380, 1976.
- K. Green and D. Elijah, “Drug effects on aqueous humor formation and pseudofacility in normal rabbit eyes,” Experimental Eye Research, vol. 33, no. 3, pp. 239–245, 1981.
- D. E. Potter, J. A. Burke, and F. W. Chang, “Alteration in ocular function induced by phenylethylamine analogs of dopamine,” Current Eye Research, vol. 3, no. 6, pp. 851–859, 1984.
- R. Mancino, L. Cerulli, A. Ricci, and F. Amenta, “Direct demonstration of dopamine D1-like receptor sites in the ciliary body of the rabbit eye by light microscope autoradiography,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 346, no. 6, pp. 644–648, 1992.
- R. A. Stone, A. M. Laties, H. C. Hemmings Jr., C. C. Ouimet, and P. Greengard, “DARPP-32 in the ciliary epithelium of the eye: a neurotransmitter-regulated phosphoprotein of brain localizes to secretory cells,” The Journal of Histochemistry and Cytochemistry, vol. 34, no. 11, pp. 1465–1468, 1986.
- D. E. Potter and J. A. Burke, “Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys,” Current Eye Research, vol. 2, no. 5, pp. 281–288, 1983.
- D. E. Potter and J. A. Burke, “An in vivo model for dissociating alpha 2-and DA2-adrenoceptor activity in an ocular adnexa: utility of the cat nictitating membrane preparation,” Current Eye Research, vol. 3, no. 11, pp. 1289–1298, 1984.
- J. Savolainen, J. Rautio, R. Razzetti, and T. Järvinen, “A novel D2-dopaminergic and alpha2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits,” The Journal of Pharmacy and Pharmacology, vol. 55, no. 6, pp. 789–794, 2003.
- E. Chu, T.-C. Chu, and D. E. Potter, “Mechanisms and sites of ocular action of 7-hydroxy-2- dipropylaminotetralin: a dopamine3 receptor agonist,” Journal of Pharmacology and Experimental Therapeutics, vol. 293, no. 3, pp. 710–716, 2000.
- Q. A. Mekki, S. M. Hassan, and P. Turner, “Bromocriptine lowers intraocular pressure without affecting blood pressure,” The Lancet, vol. 1, no. 8336, pp. 1250–1251, 1983.
- Q. A. Mekki, S. J. Warrington, and P. Turner, “Bromocriptine eyedrops lower intraocular pressure without affecting prolactin levels,” The Lancet, vol. 1, no. 8371, pp. 287–288, 1984.
- A. Lustig, “Does bromocriptine enhance the effect of drugs that reduce intraocular pressure?” Deutsche Medizinische Wochenschrift, vol. 108, no. 43, pp. 1656–1657, 1983.
- O. Elibol, C. Güler, K. Arici, A. Topalkara, and S. Demircan, “The determination of additive effect and intraocular pressure lowering effects of 0.05% bromocriptine and 0.25% timolol,” International Ophthalmology, vol. 20, no. 1–3, pp. 53–55, 1997.
- M. R. Al-Sereiti, R. F. P. Quik, A. Hedges, and P. Turner, “Antagonism by domperidone of the ocular hypotensive effect of pergolide,” European Journal of Clinical Pharmacology, vol. 38, no. 5, pp. 461–463, 1990.
- M. Virno, A. Gazzaniga, L. Taverniti, J. Pecori Giraldi, and F. de Gregorio, “Dopamine, dopaminergic drugs and ocular hypertension,” International Ophthalmology, vol. 16, no. 4-5, pp. 349–353, 1992.
- T. A. Karnezis, M. B. Murphy, R. R. Weber, K. S. Nelson, B. J. Tripathi, and R. C. Tripathi, “Effects of selective dopamine-1 receptor activation on intraocular pressure in man,” Experimental Eye Research, vol. 47, no. 5, pp. 689–697, 1988.
- J. R. Piltz, R. A. Stone, S. Boike et al., “Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure,” Journal of Ocular Pharmacology and Therapeutics, vol. 14, no. 3, pp. 203–216, 1998.
- C. Prünte and J. Flammer, “The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma,” Ophthalmology, vol. 102, no. 9, pp. 1291–1297, 1995.
- L. Magacho, F. E. Lima, M. L. Costa, F. A. Fayad, N. L. Guimarães, and M. P. Avila, “Ibopamine provocative test and glaucoma: consideration of factors that may influence the examination,” Current Eye Research, vol. 28, no. 3, pp. 189–193, 2004.
- I. F. Hepsen, H. Yilmaz, and U. C. Keskin, “The comparison of topical ibopamine 2% with tonography to identify the outflow resistance in eyes with ocular hypertension,” Ophthalmic Research, vol. 37, no. 1, pp. 17–22, 2005.
- M. Virno, R. Sampaolesi, J. Pecori Giraldi et al., “Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma,” Journal of Glaucoma, 2011.